Valuation: Black Diamond Therapeutics, Inc.

Market Cap 105M 92.13M 84.6M 78.9M 150M 10.04B 152M 1.02B 395M 4.92B 396M 387M 16.96B P/E 2026 *
-2.84x
P/E 2027 * -1.83x
Enterprise Value 105M 92.13M 84.6M 78.9M 150M 10.04B 152M 1.02B 395M 4.92B 396M 387M 16.96B EV / Sales 2026 *
19x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+5.71%
1 week+15.00%
Current month+5.68%
1 month-10.32%
3 months-18.20%
6 months-21.49%
Current year-19.55%
1 week 1.68
Extreme 1.68
2.02
1 month 1.6
Extreme 1.6
2.21
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
12.1
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 50 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
06-25Free

Director

40,000 0.0698%
06-25Free

Director

40,000 0.0698%
06-25Free

Director

40,000 0.0698%
Change 5-day change 1-year change 3-year change Capi.($)
+5.71%+15.00%-24.81%-58.32% 105M
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+2.78%+8.09%-10.14%-9.77% 23.75B
+2.20%+4.99%+11.64%+428.58% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+2.03%+3.64%+24.53%+188.37% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +3.12%+6.42%+45.85%+122.61% 23.6B
Weighted average by Cap. +1.99%+6.09%+57.34%+135.63%

Financials

2026 *2027 *
Net sales 5.56M 4.85M 4.46M 4.16M 7.88M 529M 8.01M 53.67M 20.8M 259M 20.86M 20.41M 894M -
Net income -40.47M -35.37M -32.48M -30.29M -57.41M -3.85B -58.38M -391M -152M -1.89B -152M -149M -6.51B -70.04M -61.21M -56.2M -52.41M -99.36M -6.67B -101M -677M -262M -3.27B -263M -257M -11.27B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-07-02 US$1.955 +6.25% 725,679
26-07-01 US$1.840 -0.54% 4,375,137
26-06-30 US$1.850 +5.71% 1,883,436
26-06-29 US$1.750 +2.34% 1,154,453
26-06-26 US$1.710 +0.59% 8,578,830
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.840USD
Average target price
9.857USD
Spread / Average Target
+435.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock